Attendees
Sponsors and
Exhibitors
Agenda
Webinars
Contact us
Digital Therapeutics (DTx)
Day 1 - November 30th
| Time | Session Name | Speakers | Session description |
| 9:00 - 9:05 | Opening Remarks | Shafi Ahmed , Chief Medical Officer, Medical Realities | |
| 9:05 - 10:00 | Keynote Address |
Shane Tickell, Vice Chair of Health and Social Care, Tech UK Adam Thomas, CIO, Dudley Group NHS FT Will Smart (formerly NHS CIO 2016 – 2019), Global Director External Relations, Dedalus |
|
| 10:00 - 11:15 |
Panel Discussion: A Pharma Perspective - Deploying DTx Partnerships to go Beyond the Pill |
Johannes Munding, Associate Director Digital Health Solutions , Novartis Susanne Gruber, VP Pharma Partnerships, Sidekick Health Stephane Wolf, WW Head Digital Solutions, Ophthalmology , Novartis Thomas Geuenich, Commercial Director, Germany , Teladoc Health Dr. Klaus Suwelack, New Business Development & Innovation Management , Janssen Germany Nikos Green, Senior Venture Architect & PO Neuroscience , RoX Health GmbH Moderator - Ralf-Gordon Jahns, Managing Director , Research2Guidance |
Covid-19 has drastically accelerated the adoption of digital health solutions. The increased utilization of digital therapeutics has shown to ease the burden faced by the healthcare system during the pandemic. This shift towards digital adoption has put pressure on pharma to innovate beyond their traditional approaches. 1. What should DTx/Pharma companies look for when establishing partnerships? 2. What are the challenges being seen in these partnerships? 3. How are partnerships being used to drive DTx adoption? 4. What does the future of DTx partnerships potentially look like? |
| 11:15 - 12:00 |
Panel Discussion: The Changing Landscape - DTx & Virtual Clinical Trial Solution Impact |
Adam Samson, Senior Director, Clinical Operations and Customer Success , Curebase Markus Dahlem, CEO , Newsenselab Isabel Cassidy-Soto, Digital Health Consultant , Research2Guidance Moderator - Ralf-Gordon Jahns, Managing Director, Research2Guidance |
The pandemic has accelerated the rate at which real-world data and digital tools have been adopted to conduct clinical trials. The pandemic coupled with the appropriate technologies have caused a fundamental shift towards decentralized virtual clinical trials. Resulting in rich data sets invaluable for researching a wide range of interventions, variables, and specific patient populations. 1. What are the differences between traditional and virtual clinical trials? 2. How do DTx solutions assist in running virtual/hybrid clinical trials? 3. How do we assess the value of DTx solutions through clinical trials? 4. What are the current challenges being experienced in this space? |
| 12:00 - 12:30 |
Neural Digital Therapeutics - The Next Wave of Precision Medicine |
Emil Hewage, Co-Founder & CEO, BIOS Health | DNA sequencing opened up a new field of precision medicine; now, AI is doing the same for the nervous system. The brain sends our bodies vast amounts of information every second of every day, but currently there is no data-driven insight into the nervous system, meaning feedback on treatment efficacy can take months. The next wave of healthcare will be driven by neural interfaces and AI that, for the first time, can read and write the body's neural ‘code' to understand and correct those signals in real-time. Neural digital therapies will use read/write software to create more precise and effective pharmaceuticals, digital biomarkers, and even software-delivered treatments direct to the nervous system. |
| 12:30 - 13:00 | The Emergence of Digital Health Ecosystems | Tobias Silberzahn, Partner, McKinsey | |
| 13:00 - 14:30 | Lunch and Networking | ||
| 14:30 - 15:00 | Fireside Chat | Big Health | |
| 15:00 - 15:30 | Mechanism of Action for DTx and the Science of Allostasis | Chris Wasden, Head of Pharma Speciality Solutions & Corporate Strategy, Happify | |
Day 2 - December 1st - Stage 3
| Time | Session Name | Speakers | Session description |
| 9:00 - 9:45 | Session Announced Soon | Galen Growth | |
| 9:45 - 10:05 | Addressing the burden of systemic inflammation with digital therapeutics | Pierre Bonnat, CEO , Neurodigit X | |
| 10:05 - 10:30 |
Can avatars play a role in the future of healthcare? |
Alex Merckx, Director of Marketing and Partnerships, Cognitant | |
| 10:30 - 11:30 | Coffee Break and Networking | ||
| 11:30 - 12:45 |
SAPiO Showcase |
11:30 - 11:45 - Orbia (virtual) 11:45 - 12:00 - Vyasa (Virtual) 12:00 - 12:15 - Tag n Trac (Virtual) 12:15 - 12:30 - Chekkit (In-person) 12:30 - 12:45 - Laura (In-person) |
|
| 12:45 - 13:00 | Session Announced Soon | Thomas Oliver, Founder/CEO, Omnos | |
| 13:00 - 14:30 | Lunch and Networking | ||
| 14:30 - 15:00 | DTX Panel discussion. Presented by the Founders of DTx Impact, an innovative new DTx advisory service |
Tony Kypreos, Advisory Council Member & Venture Partner, UN Sustainable Development Goals Professor Shafi Ahmed, Chief Medical Officer, Medical Realities Dr. Tal Mahmud, Advisory Board Member, Digital Healthcare Show & GP Partner |
|
| 15:00 - 15:30 | Session Announced Soon | Bene Studio | |
| 15:30 - 16:15 | Session Announced Soon | Galen Growth |
Research2Guidance is a management consultancy specializing in the digital health market. We support established healthcare companies and start-ups with insights, strategic advice, and hands-on partnership building.
We do this by providing market and competitor insights (research) and strategy advice (guidance). We facilitate partnerships creation between best-in-class innovators and established healthcare companies, helping them align their service offerings and business models.
We strive for excellence in all we do. Our consultants are 100% dedicated to digital health.
Based in Berlin, we work on projects around the world. Supporting traditional healthcare companies like pharmaceutical, health insurance, med-tech companies, medical institutions, start-ups, and enterprises that want to enter the healthcare market using digital-enabled business models and solutions.
Digital Therapeutics (DTx) are transforming the standard of care and potentially closing the gap in prevention and treatment.
This fast-growing billion USD market and the opportunity it presents to improve personalized health outcomes at scale has ignited interest from different health care stakeholders, including pharma, who have started to explore this space through investments and strategic partnerships.
Some of the questions that the session will address are:
- What will it take to scale DTx across different countries?
- Which business models may prove to be most successful?
- How can pharma leverage technology to improve the real-world performance drugs and create stand-alone DTx intervention?
- What will it take for payers to adopt DTx, and how will they pay?
We invite you to be part of and engage in inspiring discussions with our speakers, innovators, and change-makers in this industry.
No matter what you specialise in, whether your company is already building groundbreaking digital therapeutics, or you hope to invest in those who do, or if you are simply want to find the best solutions for your clients and patients, this event is for you.
Join us to hear first-hand cases and examples from leading global DTx, pharma, insurers, and digital innovators.
As they demonstrate new commercial models to accelerate clinical trials, novel value chains, service offerings, patient engagement strategies, and strategic partnerships that have led to market success or lessons learned, as well as different business and reimbursement models.
“As software and health care converge to create digital therapeutics, this new breed of life sciences technology is helping to transform patient care and deliver better clinical outcomes.“
Deloitte
“Digital Therapeutics hold tremendous potential to address unmet medical needs in patients, especially now.”
Joris Van Dam, Executive Director, Head of Digital Therapeutics, Novartis
Previous
Next
Learn
from series of high-level keynote presentations and case studies on how you can use DTx to solve your and your clients' problems
Network
with fellow industry leaders who strive to be at the forefront of innovation and build long-lasting relationships
Drive
the next wave of innovation by liaising directly with leading DTx investors and providers to make sure your opinions and problems are heard
Discover
the most exciting new innovation from both disruptive startups and established market leaders before the rest of the world
Network
with fellow investors and mentors across multiple fields to share portfolio practices and discuss business goals
Build
unique market insights as you liaise directly with leading buyers and providers to help guide your future investment decisions
Showcase
your unique innovations through our stage and exhibitions to countless leading investors and buyers. Secure your spot now before they run out
Collaborate
with your buyers and investors directly to help guide new business opportunities and secure your product-market fit
Accelerate
and improve your development process by learning from the best practices of fellow industry leaders